AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 528413: Flavone, 3,5,7-trihydroxy, tris-TMS

Chemical compound data from PubChem database. IUPAC Name: 2-phenyl-3,5,7-tris(trimethylsilyloxy)chromen-4-one. Molecular Formula: C24H34O5Si3. Molecular Weight: 486.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525346: Methane, bis(tert-butylthio)-

Chemical compound data from PubChem database. IUPAC Name: 2-(tert-butylsulfanylmethylsulfanyl)-2-methylpropane. Molecular Formula: C9H20S2. Molecular Weight: 192.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528970: Cyclohex-2-en-1-ol, 2,4,4-trimethyl-3-(3-oxobutyl)

Chemical compound data from PubChem database. IUPAC Name: 4-(3-hydroxy-2,6,6-trimethylcyclohexen-1-yl)butan-2-one. Molecular Formula: C13H22O2. Molecular Weight: 210.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Building Non-Profit Capacity and Community Partnerships: Findings from the Communities Empowering Youth (CEY) Evaluation, 2006-2010

This evaluation included annual surveys of the organizations receiving CEY funding over the program's three-year grant cycle. The survey measured changes in two types of capacity: (1) organizational capacity of each lead organization and their partner organizations, and (2) partnership capacity.

<b>Units of Response: </b>Nonprofit organizations

<b>Type of Data: </b>Survey

<b>Tribal Data: </b>No

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>One-time

<b>SORN: </b>https://www.federalregister.gov/documents/2015/04/02/2015-07440/privacy-act-of-1974-system-of-records-notice

<b>Data Use Agreement: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Data Use Agreement Location: </b>https://www.icpsr.umich.edu/web/ICPSR/studies/32581/datadocumentation

<b>Equity Indicators: </b>Unavailable

<b>Granularity: </b>Grant;Grantee

<b>Spatial: </b>United States

<b>Geocoding: </b>Region
Patent AT-E400775-T1: [Translated] ATOMIZATION BURNER FOR THE THERMAL BREAKING OF SULFUR CONTAINING RESIDUES

The aim of the invention is to produce a spray burner, starting from a conventional spray burner, for the atomisation and combustion of sulphur-containing residues, comprising a residue nozzle, for the introduction of sulphur-containing residue, which is surrounded by an outer nozzle, for the introduction of an atomising agent, whereby said burner is suitable for a method in which oxygen can be introduced in the cracking oven as additional oxidising agent to increase the capacity and improve the economic efficiency without the above disadvantages and limitations and is also optimised for a variable throughput of residue for atomising. Said aim is achieved whereby the residue nozzle comprises a multiplicity of individual nozzles which may be switched on and off, connected to an input for the residue, an inlet for fuel is provided and the outer nozzle is connected to an inlet for an oxygen-enriched gas stream.
Compound 529873: Pyrazine, 2-(2-pyrrylmethyl)-3,5-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 3,5-dimethyl-2-(1H-pyrrol-2-ylmethyl)pyrazine. Molecular Formula: C11H13N3. Molecular Weight: 187.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528877: Tyrosine, HFIP-PFP

Chemical compound data from PubChem database. IUPAC Name: [4-[3-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)-3-oxo-2-(2,2,3,3,3-pentafluoropropanoylamino)propyl]phenyl] 2,2,3,3,3-pentafluoropropanoate. Molecular Formula: C18H9F16NO5. Molecular Weight: 623.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400247-T1: [Translated] NEW TOPICAL USE OF BIS-ARYLIMIDAZO 1,2-A THIOLAND DERIVATIVES

The invention is a topical, anti-inflammatory medical, cosmetic, or dermatological preparation comprising at least one compound of the formula (DKH) wherein n is 1 or 2; and R<SUB>1 </SUB>and R<SUB>2</SUB>, independently of each other, are selected from the group consisting of phenyl, 2-toly, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, and 4-methoxyphenyl. The invention also includes methods for treating or preventing itchiness, hyperreactive skin conditions, sensitive skin, photostress, impure skin, the effects of UV radiation, and irritation comprising applying said preparation to the skin.
Managed Care Individual Provider Network Data: March 31, 2014

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. For more information, check out:  http://www.health.ny.gov/health_care/managed_care/.
Compound 530320: Hexadecanoic acid, 2-methyl-2-trimethylsilyloxy, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-methyl-2-trimethylsilyloxyhexadecanoate. Molecular Formula: C21H44O3Si. Molecular Weight: 372.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Circular RNA hsa_circ_0008726 Targets the hsa-miR-206-3p/KLF4 Axis to Modulate 4,4’-Methylene Diphenyl Diisocyanate-Glutathione Conjugate-Induced Chemokine Transcription in Macrophages

Occupational exposure to 4,4’-methylene diphenyl diisocyanate (MDI), the most widely used monomeric diisocyanate (dNCO), is associated with occupational asthma (OA) development. Recruitment of immune cells to the lung microenvironment via secreted chemokines by alveolar macrophages may plays important roles during asthma pathogenesis. Our prior studies identified MDI/MDI-GSH-exposure downregulates endogenous human/murine(hsa/mmu)-microRNA(miR)-206-3p, resulting in the activation of mmu/hsa-miR-206-3p-regulated signaling including KLF4-mediated signaling in MØs. The hsa-miR-206-3p-regulated signaling activation leading to induction of chemokines and chemotaxis activities of immune cells. However, the underlying molecular mechanism(s) by which MDI/ MDI in the form of MDI-GSH conjugate exposure downregulated endogenous hsa-miR-206-3p expression is unclear. Circular RNAs (circRNAs) play important roles in many different biological processes by targeting endogenous miRs, affecting protein translation and gene transcription in different cell types. The circRNA expression can be regulated via outside stimuli exposures; however, whether MDI-exposure influence circRNAs expression is unknown. Several circRNAs have been identified to regulate hsa-miR-206-3p levels through miR binding/targeting. We hypothesize that MDI-exposure induces endogenous circRNA(s) to regulate hsa-miR-206-3p in MØs. The first aim of this study was to identified candidate hsa-miR-206-3p-binding circRNA(s) that can be regulated by MDI/MDI-GSH regulated. The second aim of this study was to examine whether MDI/MDI-GSH regulated hsa-miR-206-3p-binding circRNA(s) can indeed regulate the endogenous hsa-miR-206-3p in MØs. After identified the roles of endogenous circRNA(s) in regulation of endogenous hsa-miR-206-3p after MDI/MDI-GSH-exposure, we investigated the roles of circRNAs in regulation of hsa-miR-206-3p-mediated M2 macrophage-associated markers and chemokines’ expressions in relation to the exposure to MDI.
Compound 528711: 1-(Methyltetrasulfanyl)prop-1-ene

Chemical compound data from PubChem database. IUPAC Name: 1-(methyltetrasulfanyl)prop-1-ene. Molecular Formula: C4H8S4. Molecular Weight: 184.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528121: 2-Ethylthio-3-methylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 2-ethylsulfanyl-3-methylpyrazine. Molecular Formula: C7H10N2S. Molecular Weight: 154.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for South Carolina

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 525528: (3-Chloro-4-hexyloxy-phenyl)-acetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-chloro-4-hexoxyphenyl)acetate. Molecular Formula: C15H21ClO3. Molecular Weight: 284.78. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Weekly Differences in Cumulative COVID-19 Vaccination Coverage and Comparison Between 2024–25 and 2023–24 Among Adults 18 Years, Overall, by Selected Demographics

• Weekly COVID-19 Vaccination Coverage and Comparison among adults 18 Years and Older by Jurisdiction

 • Weekly estimates of COVID-19 vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html).

 • Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 COVID-19 vaccines were first available at the end of August 2024.
TEDS 2011 Discharges

This is a 2011 Treatment Episode Data Set (TEDS) annual report showing discharges for people aged 12 and older from substance abuse treatment. The report provides information on treatment completion, length of stay in treatment, and demographic and substance abuse characteristics of discharges from alcohol or drug treatment in facilities that reported to individual state administra-tive data systems. The report represents forty-nine states and jurisdictions for discharges aged 12 and older occurring in 2011. Mississippi, Pennsylvania, and West Virginia submitted no data or incomplete data for 2011 and are excluded from this report.
Compound 526643: 3-O-Acetyl-1,4-Anhydro-2,5-di-O-methyl-L-fucitol

Chemical compound data from PubChem database. IUPAC Name: [4-methoxy-2-(1-methoxyethyl)oxolan-3-yl] acetate. Molecular Formula: C10H18O5. Molecular Weight: 218.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Differentiation of monocytes into multinucleated giant bone-resorbing cells: two-step differentiation induced by nurse-like cells and cytokines

Bone resorption in the joints is the characteristic finding in patients with rheumatoid arthritis (RA). Osteoclast-like cells are present in the synovial tissues and invade the bone of patients with RA. The characteristics of these cells are not completely known. In the work reported here, we generated these cells from peripheral-blood monocytes from healthy individuals. The monocytes were co-cultured with nurse-like cells from synovial tissues of patients with RA (RA-NLCs). Within 5 weeks of culture, the monocytes were activated and differentiated into mononuclear cells positive for CD14 and tartrate-resistant acid phosphatase (TRAP). These mononuclear cells then differentiated into multinucleated giant bone-resorbing cells after stimulation with IL-3, IL-5, IL-7, and/or granulocyte-macrophage-colony-stimulating factor. TRAP-positive cells with similar characteristics were found in synovial fluid from patients with RA. These results indicate that multinucleated giant bone-resorbing cells are generated from monocytes in two steps: first, RA-NLCs induce monocytes to differentiate into TRAP-positive mononuclear cells, which are then induced by cytokines to differentiate into multinucleated giant bone-resorbing cells.
Patent AT-E400586-T1: [Translated] RECEPTORS FOR HUMAN INTERLEUKIN-12

The present disclosure is directed to IL-12 receptor proteins comprising a complex of the beta1 receptor protein with the beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity. When expressed in host cells the nucleic acid gives rise to substantially homogeneous IL-12 receptor proteins. The invention relates to antibodies capable of binding to cells expressing the IL-12 receptor molecules for use in the treatment of an autoimmune dysfunction.
CCWIS Design, Software Repository, and CCWIS Options Presentation

This DSS presentation describes the Comprehensive Child Welfare Information System (CCWIS) Design Requirements, as defined by Federal Regulations 45 CFR 1355.53, the CCWIS Software Repository, as defined by Federal Regulations 45 CFR 1355.52(h), and CCWIS Options, as defined by Federal Regulations 45 CFR 1355.54.

Metadata-only record linking to the original dataset. Open original dataset below.
2012 Uniform Reporting System (URS) Tables for Puerto Rico

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528868: 5,6-Dimethyl-2,3,7-trithiabicyclo[2.2.1]heptane

Chemical compound data from PubChem database. IUPAC Name: 5,6-dimethyl-2,3,7-trithiabicyclo[2.2.1]heptane. Molecular Formula: C6H10S3. Molecular Weight: 178.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 CMHS Uniform Reporting System (URS) Table for Northern Mariana Islands

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Northern Mariana Islands for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Foster Care: A Path to Reunification – Part 1

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

Background
          In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice.
        
        
          Method
          Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10), and treatment compliance was measured using a physician-rated 4 point categorical scale.
        
        
          Results
          A total of 2128 patients initiated treatment (as monotherapy) with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients.
        
        
          Conclusion
          Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.
Compound 529087: 11H-Pyrido[2,1-b]quinazolin-11-one, 6,7,8,9-tetrahydro, 7-methyl

Chemical compound data from PubChem database. IUPAC Name: 7-methyl-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-11-one. Molecular Formula: C13H14N2O. Molecular Weight: 214.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399629-T1: [Translated] DEVICE FOR HANDLING TOOLS

The invention concerns a device (1) for manipulating tools comprising two parts, said device being of the type consisting of a frame and at least one tray forming a table, designed to receive the mold. The invention is characterized in that it comprises two horizontally arranged trays (6, 9-7, 8) one of which is arranged sliding on the frame to be mobile in translation relative to the other tray, from a close position to a remote position and inversely, so as to enable the tool to be manually opened and closed.
Severe hypomagnesaemia with tetany following ESHAP protocol

Background
          One patient with B-cell Non-Hodgkin's Lymphoma developed severe hypomagnesaemia and tetany 15 days after the first course of treatment with ESHAP protocol. This prompted a careful look at the incidence and severity of hypomagnesaemia during treatment with this combination chemotherapy.
        
        
          Method
          This patient and two further patients having the same treatment were monitored for hypomagnesaemia throughout their treatment period.
        
        
          Result
          All three patients developed significant hypomagnesaemia requiring intravenous magnesium infusion in the second and third weeks after treatment though not after every course of chemotherapy.
        
        
          Conclusions
          ESHAP protocol is often associated with significant hypomagnesaemia two to three weeks after treatment. Therefore, serum magnesium level should be monitored throughout the treatment period.
Compound 526327: 2,3-Dibromo-7-chlorodibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 2,3-dibromo-7-chlorodibenzo-p-dioxin. Molecular Formula: C12H5Br2ClO2. Molecular Weight: 376.43. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Maryland PRAMS 2006-2014 Surveillance and Selected Healthy People 2020 Objectives

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated 8/14/2024. 


Results from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS) survey of new mothers who delivered live births in the years 2006 through 2014 for selected Healthy People 2020 objectives. The two missing values for "Increase abstinence from binge drinking*** among pregnant women." are <100%. [*PRAMS data includes only information on pregnancies that end in live birth. **First trimester defined by PRAMS as <13 weeks. ***Binge drinking = 4 or more drinks in a two hour sitting, starting 2009 births.  Prior to 2009, binge drinking = 5 or more drinks in one episode.]
Compound 528749: 1,3,5-Dithiazine, perhydro-2,4-dimethyl-6-pentyl

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-6-pentyl-1,3,5-dithiazinane. Molecular Formula: C10H21NS2. Molecular Weight: 219.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Immunization Survey Adult COVID Module (NIS-ACM): Vaccination Status and Intent by Demographics

National Immunization Survey Adult COVID Module (NIS-ACM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent by demographics. 

Following collection of August 2021 survey data, an error in data processing led to incorrect categorization of some survey respondents; some respondents who should have been categorized as MSA: Principal City instead were categorized as MSA: Non-Principal City. Data downloaded during the period September 12, 2021 through September 30, 2021 may have incorrect estimates by MSA status, SVI of county of residence, and political leaning of county of residence.
Dabigatran etexilate

Dabigatran Etexilate is a generic anticoagulant medication that helps prevent blood clots by inhibiting thrombin, a key clotting factor. Available as oral capsules in 75mg, 110mg, and 150mg strengths, it's prescribed for conditions like atrial fibrillation or after certain surgeries. Manufactured by Hetero Labs Ltd. III and others, it's a prescription drug. This information was generated using AI and is provided for informational and research purposes only.